916045-29-9

Upstream product

• 916045-28-8 (R)-3-(3,4-dimethoxybenzyloxy)-1-triisopropylsilyloxy-2-[(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylenenonadeca-2,6,13,17-tertaen-1-yloxy]propane 
• 916045-27-7 (R)-3-(3,4-dimethoxybenzyloxy)-1-triisopropylsilyloxy-2-propanol 
• 916045-41-5 1-bromo-3,8,8,14,18-pentamethyl-11-methylene-nonadeca-2,6,13,17-tetraene 
• 19953-93-6 (2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylenenonadeca-2,6,13,17-tetraen-1-ol 

Downstream Products

• 916045-30-2 methyl (R)-3-(3,4-dimethoxybenzyloxy)-2-[(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylenenonadeca-2,6,13,17-tertaen-1-yloxy]propanoate 

Relevant academic research and scientific papers

MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF

The present invention provides novel moenomycin analogs as well as pharmaceutical compositions thereof, methods of synthesis, and methods of use in treating an infection by administering an inventive compound to a subject in need thereof. The moenomycin a

Degradation and reconstruction of moenomycin A and derivatives: Dissecting the function of the isoprenoid chain

Moenomycin A is the only known natural product that inhibits peptidoglycan biosynthesis by binding the bacterial transglycosylases. We describe a degradation/reconstruction route to manipulate the reducing end of moenomycin A. A comparison of the biological and enzyme inhibitory activity of moenomycin A and an analogue containing a nerol lipid in place of the natural C25 lipid chain provides insight into the role of the moenocinol unit. Our results show that a lipid chain having ten carbons in moenocinol is sufficient for enzyme inhibition, but a longer chain is required for biological acitivity, apparently because the molecule must partition into biological membranes to reach its target in bacterial cells. Copyright